MGNX
Macrogenics Inc

4,040
Mkt Cap
$109.44M
Volume
954,911.00
52W High
$3.00
52W Low
$0.9896
PE Ratio
-1.43
MGNX Fundamentals
Price
$1.70
Prev Close
$1.73
Open
$1.68
50D MA
$1.61
Beta
1.42
Avg. Volume
1.04M
EPS (Annual)
-$1.07
P/B
1.63
Rev/Employee
$439,771.26
Loading...
Loading...
News
all
press releases
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?
MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...
MarketBeat·14d ago
News Placeholder
More News
News Placeholder
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts
Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...
MarketBeat·22d ago
News Placeholder
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
Zacks·23d ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above 50 Day Moving Average - What's Next?
MacroGenics (NASDAQ:MGNX) Shares Cross Above 50-Day Moving Average - Here's What Happened...
MarketBeat·24d ago
News Placeholder
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Zacks·1mo ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Hold" at Zacks Research
Zacks Research cut shares of MacroGenics from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
MarketBeat·1mo ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Shares Pass Above 50 Day Moving Average - Should You Sell?
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat reports. One equities...
MarketBeat·2mo ago
News Placeholder
EcoR1 Capital LLC Purchases New Shares in MacroGenics, Inc. $MGNX
EcoR1 Capital LLC acquired a new stake in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor...
MarketBeat·2mo ago
News Placeholder
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Moderate Buy" from Brokerages
MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One...
MarketBeat·2mo ago
<
1
2
...
>

Latest MGNX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.